Atherosclerosis and cardiovascular risk reduction with PPAR agonists (Q37049636)

17 August 2017

1 reference

title

Atherosclerosis and cardiovascular risk reduction with PPAR agonists (English)

1 reference

17 August 2017

1 reference

1

Johanna Kuusisto

0 references

Markku Laakso

series ordinal

3

object named as

Markku Laakso

1 reference

17 August 2017

Laura Andrulionyte

2

1 reference

PubMed ID

18173954

17 August 2017

language of work or name

1 reference

1 October 2007

1 reference

Current Atherosclerosis Reports

17 August 2017

1 reference

17 August 2017

9

1 reference

17 August 2017

4

1 reference

17 August 2017

274-280

1 reference

https://scigraph.springernature.com/pub.10.1007/s11883-007-0033-4

17 August 2017

0 references

cites work

PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells

1 reference

https://api.crossref.org/works/10.1007%2FS11883-007-0033-4

PPARalpha activators inhibit tissue factor expression and activity in human monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-007-0033-4

Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-007-0033-4

CLA-1/SR-BI Is Expressed in Atherosclerotic Lesion Macrophages and Regulated by Activators of Peroxisome Proliferator-Activated Receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-007-0033-4

Peroxisome proliferator activated receptors: transcriptional regulators of adipogenesis, lipid metabolism and more....

21 January 2018

1 reference

12 December 2020

PPAR agonists in the treatment of atherosclerosis

1 reference

12 December 2020

Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study

1 reference

12 December 2020

Single nucleotide polymorphisms of the peroxisome proliferator-activated receptor-alpha gene (PPARA) influence the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial

1 reference

12 December 2020

Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes

1 reference

12 December 2020

Peroxisome proliferator-activated receptor (PPAR) agonists decrease lipoprotein lipase secretion and glycated LDL uptake by human macrophages

1 reference

12 December 2020

New targets for PPARgamma in the vessel wall: implications for restenosis

1 reference

12 December 2020

Alanine for proline substitution in the peroxisome proliferator-activated receptor gamma-2 (PPARG2) gene and the risk of incident myocardial infarction

1 reference

12 December 2020

Peroxisome proliferator-activated receptor gamma: the more the merrier?

1 reference

12 December 2020

Peroxisome Proliferator-activated Receptor α Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-κB and AP-1

1 reference

12 December 2020

Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome

1 reference

12 December 2020

Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates

1 reference

12 December 2020

Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study

1 reference

12 December 2020

Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

1 reference

12 December 2020

Peroxisome proliferator-activated receptor agonists, hyperlipidaemia, and atherosclerosis.

1 reference

12 December 2020

The PPARdelta agonist GW0742X reduces atherosclerosis in LDLR(-/-) mice

1 reference

12 December 2020

A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity

1 reference

12 December 2020

An overview on biological mechanisms of PPARs.

1 reference

12 December 2020

Association of the Pro12Ala polymorphism in the PPAR-gamma2 gene with 3-year incidence of type 2 diabetes and body weight change in the Finnish Diabetes Prevention Study

1 reference

12 December 2020

Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus

1 reference

12 December 2020

Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women

1 reference

12 December 2020

Peroxisome proliferator-activated receptor alpha gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease

1 reference

12 December 2020

Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells

1 reference

12 December 2020

A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport

1 reference

12 December 2020

Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program

1 reference

12 December 2020

PPARdelta regulates glucose metabolism and insulin sensitivity

1 reference

12 December 2020

Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications

1 reference

12 December 2020

PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines

1 reference

12 December 2020

Peroxisome proliferator-activated receptor delta (PPARdelta )-mediated regulation of preadipocyte proliferation and gene expression is dependent on cAMP signaling

1 reference

12 December 2020

Single nucleotide polymorphisms of PPARD in combination with the Gly482Ser substitution of PGC-1A and the Pro12Ala substitution of PPARG2 predict the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial.

1 reference

12 December 2020

PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis

1 reference

12 December 2020

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

1 reference

12 December 2020

PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway

1 reference

12 December 2020

The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation

1 reference

12 December 2020

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

12 December 2020

Variation in the PPARα gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects

1 reference

12 December 2020

PPARs: therapeutic targets for metabolic disease

1 reference

12 December 2020

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

12 December 2020

Ala12Ala genotype of the peroxisome proliferator-activated receptor gamma2 protects against atherosclerosis

1 reference

12 December 2020

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

1 reference

12 December 2020

The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses

1 reference

12 December 2020

[Commentary to the article: Kahn SE, Haffner SM, Heise MA, et al. ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-43]

1 reference

12 December 2020

PPAR activators inhibit endothelial cell migration by targeting Akt.

1 reference

12 December 2020

Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus

1 reference

12 December 2020

Peroxisome proliferator-activated receptors in inflammation control

1 reference

12 December 2020

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

1 reference

12 December 2020

10.1007/S11883-007-0033-4

Identifiers

DOI

1 reference

17 August 2017

1 reference

PubMed ID

18173954